IGFBP-rp1/IGFBP-7 Antibody (292917) [Unconjugated]

• Reactivity: Mu
• Applications: IHC
• Clone: 292917
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated
• Concentration: LYOPH

IGFBP-rp1/IGFBP-7 Antibody (292917) [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant mouse IGFBP‑rp1/IGFBP‑7
  Ser28-Leu281 (Arg94Lys)
  Accession # A0A5E1
• Specificity: Detects mouse IGFBP‑rp1/IGFBP‑7 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rat
• Gene: IGFBP7
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 8-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGFBP-rp1/IGFBP-7 Antibody (292917) [Unconjugated]

• angiomodulin
• FSTL2
• IBP-7
• IGFBP7
• IGFBP-7
• IGFBP-7PGI2-stimulating factor
• IGFBP-7v
• IGFBPrp1
• IGFBP-rp1
• insulin-like growth factor binding protein 7
• insulin-like growth factor-binding protein 7
• MAC25 protein
• Mac25
• MAC25IGF-binding protein 7
• Prostacyclin-stimulating factor
• PSF
• PSFAGM
• TAF
• Tumor-derived adhesion factor

Background

Insulin-like growth factor (IGF) binding protein-related protein 1 (IGFBP-rp1), also known as IGF binding protein-7 (IGFBP-7) and Mac25 is a 31-37 kDa secreted glycoprotein that belongs to the IGFBP superfamily of molecules (1, 2). Members of this superfamily are characterized by the presence of 10-12 conserved cysteines in the first third of the molecule, and the partial conservation of an xCGCCxxC octapeptide motif that exists in an N-terminal IGFBP domain (1, 3). Mouse IGFBP-7 cDNA encodes a 281 amino acid (aa) precursor protein that contains a putative 25 aa signal peptide and a 256 aa mature region. The mature protein contains an N-terminal 43 aa IGFBP domain that is followed by a 52 aa Kazal-type serine proteinase inhibitor domain and a 105 aa C-terminal Ig-like C2-type domain (4, 5). The molecule is known to contain about 4 kDa of carbohydrate and believed to undergo phosphorylation (6). Mature mouse IGFBP-7 is 95% and 91% aa identical to mature rat and human IGFBP-7, respectively. Cells known to express IGFBP-7 include osteoblasts, select skeletal muscle fibers, visceral and vascular smooth muscle cells, breast epithelium, ciliated epithelium, renal tubular epithelium, astrocytes and oligodendroglia, and vascular endothelium in all tissues except brain (7). IGFBP-7 will bind both IGF-I and insulin, albeit at low affinity. When bound to IGF-I, it participates in growth promoting effects (8). Alternatively, IGFBP-7 by itself is an inhibitor of cell proliferation (6). Thus, its function is unclear. It is known to bind heparin, syndecan-1 and chemokines (8, 9). Based on human studies and aa conservation in relevant regions, mouse IGFBP-7 might be be expected to undergo proteolytic cleavage extracellularly (8). This will create an 8 kDa, 72 aa subunit (containing the IGFBP domain) that is disulfide-linked to a 25 kDa, 184 aa C-terminal subunit. Cleavage will reduce IGF-I bonding activity and the promotion of IGF-dependent cell proliferation.

1. Hwa, V. et al. (1999) Endocr. Rev. 20:761. 
2. Kim, H-S. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12981. 
3. Oh, Y. et al. (1996) J. Biol. Chem. 271:30322. 
4. Kato, M.V. et al. (1996) Oncogene 12:1361. 
5. Kato, M.V. (2000) Mol. Med. 6:126.
6. Wilson, H-M. et al. (2002) Cell Growth Differ. 13:205.
7. Degeorges, A. et al. (2000) J. Histochem. Cytochem. 48:747.
8. Ahmed, S. et al. (2003) Biochem. Biophys. Res. Commun. 310:612.
9. Nagakubo, D. et al. (2003) J. Immunol. 171:553.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IGFBP-rp1/IGFBP-7 Antibody (MAB21201)(2)

Publications using MAB21201

• M Akiel, C Guo, X Li, D Rajasekara, RG Mendoza, CL Robertson, N Jariwala, F Yuan, MA Subler, J Windle, DK Garcia, Z Lai, HH Chen, Y Chen, S Giashuddin, PB Fisher, XY Wang, D Sarkar IGFBP7 Deletion Promotes Hepatocellular Carcinoma Cancer Res., 2017-06-15;0(0):. 2017-06-15 [PMID: 28619711] (IHC-P, Western Blot, Mouse)
• Chen RY, Chen HX, Lin JX In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression. J. Exp. Clin. Cancer Res., 2010-02-16;29(0):13. 2010-02-16 [PMID: 20158915] (IHC-Fr, Western Blot, Mouse)

Bioinformatics

• Gene Symbol: IGFBP7
• Uniprot:
  • A0A5E1()